NewsFree365
--°
Business
7 views

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

CNBC Verified Source

Syndicated via official news feed

Explore all Business stories

Syndicated feed content with full publisher credit.

Business Desk

More in Business

Continue reading verified coverage and related developments on this desk.

View All